H-HIS-GLY-GLY-OH | CAS:32999-80-7

We serve H-HIS-GLY-GLY-OH CAS:32999-80-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
H-HIS-GLY-GLY-OH

Chemical Name:H-HIS-GLY-GLY-OH
CAS.NO:32999-80-7
Synonyms:H-HIS-GLY-GLY-OH
2-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]acetyl]amino]acetic acid
IAMIN
histidylglycylglycine
 
Physical and Chemical Properties:
Molecular Formula C10H15N5O4
Molecular Weight 269.25700
 
Specification:
Appearance:White blue powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Applicationd as the raw material in cosmetic.



Contact us for information like H-HIS-GLY-GLY-OH chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,histidylglycylglycine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,histidylglycylglycine Use and application,H-HIS-GLY-GLY-OH technical grade,usp/ep/jp grade.


Related News: “Our priority is not only to protect and inform the residents of Boston but also to help this man continue to recover.(+)-Dibenzoyl-D-tartaric acid manufacturer TSA notified airlines Saturday about the restrictions. CNN is reaching out to TSA for comment.(R)-5-(2-aminopropyl)-1-(3-benzyloxypropyl) indoline-7-carbonitrile supplier China has granted conditional approval to its first self-developed treatment for Alzheimer’s disease, a move that may point to revived opportunities in a therapeutic area where drugmakers have burned billions of dollars without yielding a validated new drug.3-Mercaptopropyltriethoxysilane vendor China has granted conditional approval to its first self-developed treatment for Alzheimer’s disease, a move that may point to revived opportunities in a therapeutic area where drugmakers have burned billions of dollars without yielding a validated new drug.The Company’s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs).